Details of the Drug

General Information of Drug (ID: DMYBWL9)

• Drug Name: Imlunestrant
• Synonyms: Imlunestrant; UNII-9CXQ3PF69U; Imlunestrant [USAN]; LY3484356; 9CXQ3PF69U; 2408840-26-4; LY-3484356; WHO 12039; (5R)-5-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5H-(1)benzopyrano(4,3-c)quinolin-2-ol; 5H-(1)Benzopyrano(4,3-c)quinolin-2-ol, 5-(4-(2-(3-(fluoromethyl)-1-azetidinyl)ethoxy)phenyl)-8-(trifluoromethyl)-, (5R)-; IMLUNESTRANT [INN]; CHEMBL5095183; SCHEMBL22002569; GTPL12896; UVBQMXOKKDCBJN-MUUNZHRXSA-N; BDBM443429; GLXC-26209; US10654866, Example 1A; EX-A6123; Ly 3484356; Example 1B {WO2020014435A1]; HY-145572; CS-0376104; (5R)-5-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 3	[1]

• Drug Type: Small molecule
• Chemical Identifiers:
  Formula: C29H24F4N2O3
  Canonical SMILES: C1C(CN1CCOC2=CC=C(C=C2)C3C4=C5C=CC(=CC5=NC=C4C6=C(O3)C=C(C=C6)C(F)(F)F)O)CF
  InChI: InChI=1S/C29H24F4N2O3/c30-13-17-15-35(16-17)9-10-37-21-5-1-18(2-6-21)28-27-23-8-4-20(36)12-25(23)34-14-24(27)22-7-3-19(29(31,32)33)11-26(22)38-28/h1-8,11-12,14,17,28,36H,9-10,13,15-16H2/t28-/m1/s1
  InChIKey: UVBQMXOKKDCBJN-MUUNZHRXSA-N
• Cross-matching ID:
  PubChem CID: 146603228
  ChEBI ID: CHEMBL5095183
  TTD ID: DON71B
• Drug-Molecule Activity Atlas (DMA)NEW: Click to Jump to the Detailed DMA Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Degrader	[1]

References

• [1] ClinicalTrials.gov (NCT04975308) EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy. U.S.National Institutes of Health.